Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Long-Term Debt Repayments (2016 - 2021)

Lexaria Bioscience's Long-Term Debt Repayments history spans 2 years, with the latest figure at -$419.0 for Q3 2021.

  • Quarterly results put Long-Term Debt Repayments at -$419.0 for Q3 2021, changed N/A from a year ago — trailing twelve months through Aug 2022 was -$419.0 (down 100.44% YoY), and the annual figure for FY2021 was $22744.0, changed.
  • Long-Term Debt Repayments for Q3 2021 was -$419.0 at Lexaria Bioscience, down from $50000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of -$419.0 in Q3 2021 to a low of -$419.0 in Q3 2021.